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Abstract: We studied centromeric SMN gene
deletions in various forms of congenital
muscular dystrophies. Our study cohort
consisted of 48 patients (43 families): 24
with merosin-positive CMD, 18 with merosindeficient CMD and 6 with muscle-eye-brain
(MEB) disease. None of the patients showed
deletions of the telomeric gene; however, the
deletion frequency of the centromeric gene
was 27%. In a multiplex family, the mildly
affected sibling, who is ambulant, had a
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Introduction
Proximal spinal muscular atrophy (SMA) is an
autosomal recessive neuromuscular disorder, which
results in loss of motor neurons in the spinal cord.
Affected individuals are classified into 3 groups that have
been mapped to chromosome 5q11.2-13.3 (1). The
survival motor neuron gene (SMN) is one of the candidate
genes of SMA. It is present in two highly homologous
copies within the SMA region. They are called telomeric
SMN (SMN1) and centromeric SMN (SMN2). These two
copies differ by two single nucleotides; one in exon 7,
which does not alter the amino acid composition, and one
in exon 8, which is an untranslated exon. Therefore, both
genes predict identical proteins. Exon 7 of the telomeric
copy is disrupted by deletion or gene conversion in more
than 95% of patients with SMA of all grades of severity
(2-4). SMN encodes a protein located within a novel
nuclear structure and interacts with RNA binding
proteins. A 38 kDa SMN protein is expressed from the
telomeric and centromeric SMN genes and is found in the
cytoplasm and nucleus. SMN is expressed at high levels in
the brain, kidney and liver, at moderate levels in skeletal
and cardiac muscle, and at low levels in fibroblasts and
lymphocytes (5,6).
There may be some clinical overlaps between SMA and
other congenital myopathies, especially when the case
does not present with fasciculations or tremors. Since the
age of onset in SMA matches that in congenital muscular

preserved centromeric copy of the SMN gene,
whereas in the severely affected sibling the
copy was missing. The centromeric copy of
the SMN gene may have a contributing role in
the phenotype of patients with CMD, as well
as other modifying genes or environmental
factors.
Key Words: Congenital muscular dystrophies,
survival motor neurongene, SMN, deletion,
SMA

dystrophies (CMD), it may be difficult to differentiate
them clinically in the absence of typical stigmata of the
individual conditions.
CMD is a clinically and genetically heterogeneous
group of muscle disorders with autosomal recessive
inheritance. CMD has been classified into several
subgroups. One subgroup of patients lacks the expression
of the laminin α 2 chain (merosin-deficient) in the skeletal
muscle basement membrane. Linkage analysis localized
the defective gene to the region of the LAMA2 merosin
locus on chromosome 6q2 (7). The LAMA2 gene is very
large, with more than 64 exons and a transcript of more
than 10 kb. Another subgroup of patients with classical
CMD has normal levels of laminin α 2 chain (merosinpositive) and basic protein defects are unknown. This
latter group is also highly heterogeneous (8).
There are other forms of CMD with structural brain
involvement. A reduced expression of laminin α 2 chain
has been reported in Fukuyama’s congenital muscular
dystrophy (FCMD), a condition almost exclusive to Japan
with typical findings of severe mental retardation and
cortical abnormalities of the brain (9). However, this
represents a secondary phenomenon, because the gene
for FCMD is on chromosome 9. Another form of CMD,
the muscle-eye-brain (MEB) disease, which is
characterized by severe mental retardation, ocular and
brain abnormalities, has recently been mapped to
chromosome 1p32-43 (10). There is evidence that the
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laminin α 2 chain is also reduced in MEB (11). The most
severe condition of the spectrum is the Walker-Warburg
syndrome (WWS), and recent data shows that WWS is
also heterogeneous.
Patients with WWS and severe lissencephaly usually
expire before age 1; nevertheless, milder forms survive
and may run a course clinically similar to MEB (12).
Finally, one peculiar form of CMD, rigid spine syndrome
with early respiratory failure, has recently been mapped
to chromosome 1p35-36 (13).
In the present study, we analyzed SMN gene deletions
in various congenital muscular dystrophies.
Materials and Methods
We analyzed 48 patients from 43 CMD families. Of
these patients, 24 were classified as having merosinpositive CMD, 18 merosin-deficient CMD and 6 MEB
disease. All patients fulfilled the necessary diagnostic
criteria for CMD and plus syndromes set by European
Neuromuscular Center (ENMC) sponsored CMD
consortium. There were 5 families with 2 siblings
affected in our patient group. Two hundred nine SMA
patients with 40 parents and 34 healthy control
individuals had previously been examined for the
deletions. Informed consent was obtained from each
patient.
DNAs were extracted from white blood cells (19
patients) and paraffin-embedded muscle tissue sections
(29 patients) by standard methods (14). The methods of

the PCR used to amplify exons 7 and exons 8 of the SMN
genes were similar to those used by Van der Steege et al.
(4). To distinguish centromeric and telomeric exons 7 and
8, each PCR product was digested with DraI and DdeI
restriction enzymes, respectively. Digestion products
were run on 2.5% agarose gel containing ethidium
bromide and visualized under UV fluorescence (Figure 1).
Results
Although we did not detect any deletion of the
centromeric copy of the SMN exon 7 and 8 in either SMA
patients (n: 209) and parents (n: 40) or the healthy
control group (n: 34), the overall centromeric deletion
frequency rate was 27% in CMD patients. Table 1 shows
the centromeric deletion frequencies of CMD subgroups
and Table 2 shows the centromeric deletions of the
families with 2 affected siblings. Family I had two siblings
with discordant phenotype; the 18-year-old sister has
never walked, whereas the 14-year-old brother originally
walked at the age of 3 years and is still ambulant. In this
family, only the severely affected sibling had the deletion
Table 1.

Centromeric deletion frequencies of the CMD subgroup.
Allele frequency
of centromeric
exon 7 deletion

Allele frequency
of centromeric
exon 8 deletion

Merosin-positive CMD

14/48 (29%)

12/48 (25%)

Merosin-deficient CMD

4/36 (11%)

2/36 (6%)

MEB

8/12 (67%)

8/12 (67%)

Patients

Table 2.

Centromeric deletions of the families with 2 affected
siblings.

Family

Figure 1.

Restriction enzyme assay of the SMN gene. (The PCR
products of exon 7 were digested with DraI and exon 8
with DdeI).

M: Molecular weight marker (φX174)
Lane 1,5: Undigested PCR products
Lane 2,4: Healthy individuals for exon 7
Lane 3: Deletion of centromeric exon 7 in the index case
Lane 6,8: Healthy individuals for exon 8
Lane 7: Deletion of centromeric exon 8 in the index case
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Centomeric
exon 7 deletion

Centomeric
exon 8 deletion

Family I

Sibling 1

-

-

(Merosin-positive CMD)

Sibling 2

+

+

Family II

Sibling 1

+

+

(Merosin-positive CMD)

Sibling 2

+

+

Family III

Sibling 1

-

-

(Merosin-deficient CMD)

Sibling 2

-

-

Family IV

Sibling 1

-

-

(Merosin-deficient CMD)

Sibling 2

-

-

Family V

Sibling 1

+

+

MEB

Sibling 2

+

+
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of the centromeric copy of the SMN gene. In the other 4
families there was no discrepancy. None of the CMD
patients showed telomeric SMN exon 7 and 8 deletion.
Discussion
In our study, centromeric SMN gene deletion
frequency was 27%. Twenty-four merosin-positive CMD,
18 merosin-deficient CMD and 6 MEB patients showed
29%, 11%, 67% deletions of the centromeric copy of
SMN exon 7, respectively. Previous reports have given an
incidence of 4-5% centromeric SMN deletion in normal
populations (15,16). Another study on the Turkish
population reports centromeric SMN deletion of exon 7
and 8 with an incidence of 9% (17). Even though our
number of control subjects was only 34, our results of
deletion incidence in CMD are still higher than these
control results. Two patients (1 merosin-positive, 1
merosin-deficient) showed centromeric exon 7 deletion
but not exon 8.
In SMA patients lacking the telomeric copy, the SMN
protein was detected. This showed that not only the
telomeric copy but also the centromeric copy produced
the SMN protein. The protein encoded by the centromeric
SMN gene is probably functionally active, as its level is
directly correlated to the clinical severity of the SMA
(5,18). The 1.5 kb SMN transcript encodes a protein of
294 amino acids. The protein is expressed in humans, is
conserved through mammalian species and shows no
homology with any known protein (3).
SMN monoclonal antibodies show several intense
dots. These structures are similar in number (2-6) and
size (0.1-1.0µ) to coiled bodies, and are found near or

associated with coiled bodies. These prominent nuclear
structures are termed gems, for Gemini of coiled bodies.
The gems appear to interact directly with the coiled
bodies that are believed to have a role in mRNA
processing. The number of gems as detected by SMN
antibodies correlates with the phenotype of the SMA
patients (19,20).
In searching for hnRNP-interacting proteins, Liu et al.
found that SMN interacts with the RGG box region of
hnRNP U, with itself, with fibrillarin and with several
novel proteins (6). Gall et al. postulate that coiled bodies
function in the assembly and sorting of snRNP complexes
for 3 RNA processing pathways: pre-mRNA splicing, RNA
processing and histone pre-mRNA 3’ end formation
(21,22).
All forms of CMD are usually severe. However, not all
CMD cases had missing centromeric copies of the SMN
gene denoting the complexity of the interactions.
Nevertheless, considering the phenotypic difference of
the two siblings in one of our multiplex families, we can
speculate that the presence of this copy may have a
potentiating role in modifying the clinical picture. In
conclusion, since RNA processing is a common biological
pathway, its disruption may have an additional
contribution to several phenotypes such as we have
demonstrated here.
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